KLOW Blend
Also known as: KLOW Stack, KLOW Protocol, Advanced Healing Blend
Buy in shop
KLOW Blend from $239/kit
5 verified vendors, ≥99% purity, COAs included.
Key Facts: KLOW Blend
- Category
- Peptide Blend
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical Research (Components)
- Administration
- Subcutaneous injection
- Typical Dose
- Standard vial dosing per protocol
- Frequency
- Once daily
- Duration
- 8-12 weeks
Mechanism of Action
KLOW stacks four peptides with overlapping repair and anti-inflammatory rationales. GHK-Cu is the copper tripeptide that supports collagen, elastin, and matrix remodeling in skin (cell and animal data). BPC-157 and TB-500 are the same pro-healing pair as the Wolverine and GLOW blends, proposed to drive angiogenesis and cell migration based on rodent studies. KPV is the new addition: a tripeptide (lysine-proline-valine) from the C-terminal tail of alpha-MSH that appears to dampen inflammation by inhibiting NF-kB signaling inside cells. Notably, KPV's anti-inflammatory effect in the gut is thought to be receptor-independent, entering intestinal cells through the PepT1 di/tripeptide transporter that is upregulated during inflammation, which is why most KPV research is oral and gut-focused.
Research Summary
There is no human trial of the KLOW blend, and three of its four components (BPC-157, TB-500, KPV) have no completed human efficacy trials at all. KPV's strongest data is in mouse colitis models, where oral KPV reduced the severity of chemically induced (DSS and TNBS) colitis, with mechanistic work showing PepT1-mediated uptake and NF-kB inhibition. GHK-Cu has the most human support, but only as topical skincare, not as an injected blend. So KLOW combines one peptide with real topical evidence (GHK-Cu) and three peptides supported mainly by animal data, then mixes and injects them in a way no study has validated. Pulling KPV out of its oral-gut context and into an injectable cosmetic-repair stack is itself an untested choice. Treat the marketed benefits as a hypothesis built from separate preclinical pieces, not a proven combination.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
Standard vial dosing per protocol
Varies by vendor formulation
Once daily
Advanced stack adding KPV for anti-inflammatory benefits. Good for gut health + healing + skin. Fasted for gut, evening for skin.
Research Dosingⓘ
Scientific studies
Advanced healing and anti-inflammatory blend
Doses from Studies
GHK-Cu 50mg, KPV 10mg, BPC-157 10mg, TB-500 10mg
Vendor Formulations - Standard KLOW formulation
Duration
8-12 weeks
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Morning or evening
Once daily
Food Recommendation
With or without food
Why This Timing?
Can be used morning for gut benefits (fasted) or evening for skin repair
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Injection site reactions
- ●Mild fatigue initially
- ●Temporary GI changes (as gut heals)
- ●Headache (rare)
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
- https://www.gastrojournal.org/article/S0016-5085(07)01852-5/abstract
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6359621/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2933142/
Research This Peptide Further
Buy in shop
KLOW Blend from $239/kit
5 verified vendors, ≥99% purity, COAs included.
Frequently Asked Questions
What does KLOW Blend do?
KLOW is a four-peptide blend that adds KPV to the GLOW mix, so it contains GHK-Cu, BPC-157, TB-500, and KPV. It is marketed for healing, anti-inflammatory, and skin and gut benefits, typically sold as a single research vial (commonly around 80 mg total). As with the other blends, none of the peptides is FDA-approved for these uses, and the KLOW combination has never been tested as a product in a clinical trial.
How does KLOW Blend work?
KLOW stacks four peptides with overlapping repair and anti-inflammatory rationales. GHK-Cu is the copper tripeptide that supports collagen, elastin, and matrix remodeling in skin (cell and animal data). BPC-157 and TB-500 are the same pro-healing pair as the Wolverine and GLOW blends, proposed to drive angiogenesis and cell migration based on rodent studies. KPV is the new addition: a tripeptide (lysine-proline-valine) from the C-terminal tail of alpha-MSH that appears to dampen inflammation by inhibiting NF-kB signaling inside cells. Notably, KPV's anti-inflammatory effect in the gut is thought to be receptor-independent, entering intestinal cells through the PepT1 di/tripeptide transporter that is upregulated during inflammation, which is why most KPV research is oral and gut-focused.
Is KLOW Blend FDA approved?
No, KLOW Blend is not currently FDA approved. Current status: Preclinical Research (Components)
What are the side effects of KLOW Blend?
Reported side effects include: Injection site reactions, Mild fatigue initially, Temporary GI changes (as gut heals), Headache (rare). Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of KLOW Blend?
Community-reported common dose: Standard vial dosing per protocol (Once daily). Range: Varies by vendor formulation. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with KLOW Blend or used in similar applications.
Glow Protocol
PreclinicalGLOW (sometimes sold as Glow Blend) is a marketing name for a three-peptide cocktail: GHK-Cu (a copper-binding tripeptide), BPC-157, and TB-500. It is pitched for skin rejuvenation, collagen support, and tissue healing, usually as a single injectable blend from compounding clinics or research suppliers. None of the three peptides is FDA-approved for these uses, and the GLOW combination has never been studied as a product in any clinical trial.
Peptide BlendWolverine Stack
PreclinicalThe Wolverine Stack is not a single drug. It is a popular nickname for combining two regenerative peptides, BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4), usually injected together for injury recovery, tendon and soft-tissue repair, and inflammation. Neither peptide is FDA-approved for human use, and the combination itself has never been tested in a human clinical trial. Almost all supporting data is from animal studies on the individual peptides.
Peptide BlendThymosin Beta-4
Clinical TrialsThymosin beta-4 (Tbeta4) is a small 43 amino acid peptide found in nearly every cell in the body, originally isolated from the thymus. Its main job is binding and sequestering G-actin, the building block of the cell's internal scaffolding, which lets it influence cell movement, wound repair, and tissue regeneration. It is researched heavily for healing of skin, cornea, and heart tissue, but it is not an FDA-approved drug. (The injectable sold as TB-500 is a synthetic fragment marketed as related to Tbeta4, not the full natural peptide.)
HealingTB-500
PreclinicalTB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
HealingGHK-Cu
Clinical TrialsGHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Skin & HairLL-37
Clinical TrialsLL-37 is the only cathelicidin antimicrobial peptide humans make, a 37-amino-acid, positively charged, helical fragment cut from a precursor protein called hCAP-18. It is a frontline player in the innate immune system, part of the body's chemical defense against bacteria, viruses, and fungi. This is mainstream, heavily studied human biology, not a fringe research peptide, though LL-37 itself is not an approved drug.
ImmuneWant updates on KLOW Blend research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.